Background
==========

Coronary heart disease (CHD) is a common chronic disease, affecting around 3.5% of the UK population \[[@B1]\]; it is the most common cause of mortality in the world \[[@B2]\] and in the UK accounted for 18% of premature deaths in men and 9% in women in 2008 \[[@B3]\]. It was ranked as the second leading cause of disability in high- and middle-income countries in 2004 \[[@B2]\].

Depression is likewise an important public health problem: it has a 12-month prevalence of around 4% \[[@B4]\] and is currently the leading cause of global disease burden in high- and middle-income countries \[[@B2]\]. For at least half of all people who experience an episode, depression is characterised by relapses, and for 10 - 20% it involves chronic symptoms \[[@B5],[@B6]\]. Depression co-occurs in a substantial proportion of patients with chronic medical conditions including CHD; and this co-occurrence is associated with poorer quality of life and increased morbidity and mortality \[[@B7],[@B8]\]. There is consistent evidence that depression is predictive of subsequent coronary events in people with established CHD and the risk of fatal cardiac events in this population is more than doubled when this is co-morbid with depression \[[@B7]\]. Mortality risk appears most strongly associated with depression onset following the acute coronary syndrome \[[@B9]\].

The association between depression and CHD appears to be related to physiological mechanisms such as altered inflammatory responses and changes in platelet aggregation \[[@B10]\], as well as to a range of health behaviours. Factors such as sedentary lifestyle, unhealthy diet, cigarette smoking and reduced adherence to exercise or medication regimens elevate the risk of adverse health outcomes \[[@B11]\]. Providing interventions that facilitate changes in health behaviour as well as impacting on depression has clear relevance for this patient group.

In the UK, most people with depression are treated in primary care \[[@B12]\], however there is limited provision within current services for its longer-term management, or for care that addresses its frequent co-morbidity with medical conditions. Improving the management of depression in people with CHD is an important goal, with the potential for benefit for both psychological and physical health outcomes. Researchers have investigated the effectiveness of pharmacological and psychological therapies with patients experiencing this combination of conditions, and systematic reviews conducted for the recent National Institute for Health and Clinical Excellence clinical guideline clearly show that these treatment approaches are effective on depression outcomes in comparison with standard care \[[@B11]\]. There is also emerging evidence for the benefit of these types of intervention on a range of physical health outcomes including glycaemic control \[[@B13]\], low-density lipoprotein cholesterol, and systolic blood pressure \[[@B14]\].

There is particular value in a coordinated treatment approach that addresses the physical and psychological needs of this patient group within primary care, and avoids the fragmentation of care delivery that can hamper the management of long-term conditions \[[@B15]\]. The links between depression and CHD are likely to be complex, but lifestyle factors appear especially important for cardiac outcomes as well as for quality of life \[[@B16]\]. It appears that certain interventions used in chronic disease management are of particular relevance. Components such as education about the condition, interventions to encourage physical exercise, systematic monitoring of the patient's response and concordance to treatment, and assisting lifestyle modification have been found to be associated with psychological improvement as well as benefiting physical health. A recent systematic review has identified benefit for depression outcomes from such community-based heart disease interventions \[[@B17]\].

The current study evaluates a novel personalised care approach using regular pro-active contact and follow-up and involving elements of *case management*. The term 'case management' was first used in the 1950s in the USA to describe the extended community services needed for discharged mental health patients, and has subsequently developed to become a widely-used approach for managing the care required by people with complex health and social care needs \[[@B18]\]. It is a systematic proactive approach used to assess and organize care using a health professional (typically a nurse or social worker), the case manager, to work collaboratively with the patient to plan and monitor treatments and supports. Key elements of this role involve using scheduled follow-ups to help develop self-management techniques; providing education about the illnesses; supporting ongoing treatments whilst addressing non-adherence or lack of improvement by adjustments or facilitating changes; and where appropriate coordinating care across the health and social care system \[[@B19]\]. In England, NHS case management has been a central aspect of the long-term conditions strategy, and is focussed explicitly on the care of those people with complex long-term needs who are at high risk of decline and unplanned reactive specialist care such as hospital admissions \[[@B20]\].

Within the current study, the personalised care approach is more broadly focused than case management which typically exclusively targets the most complex and vulnerable patients; and is delivered by means of regular telephone contacts. It is centred on collaborative working underpinned by a care plan agreed between the patient and case manager and incorporates appropriate and accessible health education and the support for self-care, using evidence based behaviour change techniques that are noted in UK health policy as the main approach to care for the majority of people with long-term conditions. The intention within this study is to evaluate an intervention that could be feasibly delivered by health professionals in primary care such as practice nurses who are in an excellent position to provide such an approach to patients in the management of chronic problems \[[@B21]\]. Discussion of cases between the case manager and an academic GP will be used each week to mirror the type of case review that is available within the primary care team.

The intervention is designed to enhance current practice with only minimal additional administration and training. It was developed on the basis of reviews of the relevant literature \[[@B22]\] and qualitative studies of patients' and health professionals' views on treatment needs for CHD and comorbid depression. This study forms part of a broader programme of research including a prospective cohort study of 803 primary care patients with coronary heart disease to explore the relationship with depression and a nested case--control study to investigate genetic and blood-biomarkers as predictors of depression \[[@B23]\].

Aims
====

This study seeks to examine the feasibility and acceptability of telephone-delivered personalised care compared with treatment as usual (TAU) for a subset of primary care CHD patients who have probable concurrent depression, and to explore the types of needs and problems identified by patients in collaboration with their case manager. The methods of the trial will also be tested to inform a definitive trial. The primary outcome to be tested will be the severity of depression features measured by the Hospital Anxiety and Depression Scale\[[@B24]\] depression sub-scale (HADS-D) at 1-, 6-, and 12-months following randomisation. Secondary outcomes tested will include measures of CHD symptoms, wellbeing, and health service utilisation.

Methods/design
==============

This study is a randomised controlled trial with randomisation by individual patients within practices recruited by the Primary Care Research Network-Greater London. The comparison is between usual primary care (control arm), and personalised care involving regular telephone follow-up by nursing health professionals in addition to usual primary care (intervention arm).

Sample size
===========

Although estimation of a definitive effect size is not the focus of this pilot study, a sample size calculation indicated that to show a mean difference between intervention and control of ≥ 3 on the HADS Depression subscale, assuming a pooled standard deviation around mean scores of 4, 30 participants per group are needed for 90% power at the 5% significance level. This is also in line with the minimum of 12 per group suggested for pilot studies \[[@B25]\]. To allow for loss to follow-up estimated at 25%, our plan was to recruit 80 participants (40 per arm) into the RCT.

Recruitment - practices
=======================

Practices in South London were eligible for inclusion if they kept a register of patients with CHD for the Quality and Outcomes Framework (QOF) and were willing to be involved in liaison concerning patients in the intervention arm where necessary. Practices already involved in the UPBEAT-UK cohort study were excluded. Recruitment commenced in October 2010. 15 general practices were approached by the Greater London Primary Care Research Network (PCRN-GL), one of eight local primary care research networks for England funded by the National Institute for Health Research Clinical Research Network (NIHR CRN) which assist in coordinating and supporting NHS primary care research, and all practices agreed to participate.

Recruitment - participants
==========================

All patients on practice case registers for CHD were sent study information and consent to contact requests by participating general practitioners. Those patients who provided consent were contacted by study researchers and assessed for depression using the HADS-D and for symptoms relating to CHD using the Modified Rose Angina Questionnaire \[[@B26]\]. Patients with symptomatic CHD (i.e. current chest pain) and a score of ≥8 on the HADS-D scale \[[@B24]\]were eligible to participate in the study. Those providing fully informed consent to participate were then randomly allocated to either to the intervention (personalised care) or the treatment as usual (TAU) arm of the study (Figure [1](#F1){ref-type="fig"}).

· Symptomatic CHD as scored on the modified Rose Angina Questionnaire \[[@B26]\]

· A score ≥8 on the depression part of the Hospital Anxiety and Depression Scale \[[@B24]\]

· Aged 18 years or over

· Temporary registrations

· Actively suicidal patients

· Psychotic depression as evidenced by delusions and/or hallucinations

· Non-English speaking

· Participants currently in hospital for treatment of their CHD

![Flow chart of the UPBEAT-UK trial.](1471-244X-12-58-1){#F1}

Randomisation
=============

Randomisation was conducted independently by the Mental Health and Neurosciences Clinical Trials Unit (CTU) at King\'s College London and allocation concealment was ensured by the CTU independent database programme. Randomisation was at patient level. A random permuted block design was used to approximately balance the numbers in the control and intervention groups.

Intervention
============

The intervention was developed following a literature review and qualitative studies that explored the views of patients and service providers concerning health needs and care delivery suitable for coronary heart disease and co-morbid depression. Patients' perspectives on treatments were examined by semi-structured interview with 30 participants of the UPBEAT-UK cohort study with probable depression (identified by PHQ-9 score) in addition to CHD, and by two focus groups involving participants with symptomatic CHD (identified by Rose Angina Questionnaire) and probable depression (by PHQ-9 score). Interviews were conducted with 12 practice nurses and 10 GPs working in practices in 4 ethnically and culturally diverse parts of South London. These studies indicated that an individualised case management-based intervention of a type that could be delivered by practice nurses was likely to be acceptable and effective.

On the basis of these investigations, we developed a tailored face-to-face assessment and telephone-delivered follow-up provided by clinically qualified case managers. Because this was an exploratory study, the case managers were members of the research team, and rather than practice nurses they were a community psychiatric nurse and a health psychologist who is also a registered nurse. Neither of the case managers is involved in collecting the follow-up data.

The case managers arrange to meet with each participant randomised to the intervention arm for an initial assessment. Central to the care model is developing a shared plan of care, and in this study the initial assessment meeting between the patient and case manager is focused on developing a personalised care plan (PCP) based on a comprehensive assessment (see Additional file [1](#S1){ref-type="supplementary-material"}). The format of the assessment materials has been specifically based on the outcome areas identified in the Department of Health green paper *Independence, Well-being and Choice*\[[@B27]\], enabling a multi-factorial assessment of each patient's physical, mental and social wellbeing and relevant environmental factors. This assessment follows UK developments towards a common assessment framework for adults \[[@B28]\]. A copy of the PCP is kept by the participant, a copy by the case manager and a copy is sent to the participant's GP. The case manager helps the participant choose up to two main problems on which to work. The focus will be on helping the patients to identify problems they think are contributing to their depression, rather than the case manager imposing their views. The case manager will provide health advice, but a key aim is to develop the patient's confidence in identifying and solving their own problems. The case managers will be familiar with a range of evidence based behaviour change interventions such as goal setting and rating importance and confidence to change (importance/confidence ruler), which they will use to enhance the patient's self- efficacy in self management. The case managers also provide written information where necessary about depression, CHD and other health problems, and about appropriate local resources for participants to access, as well as liaising with other health professionals involved in the participant's care as appropriate.

The initial assessment will last up to an hour, and patients will be followed up by the case manager by telephone (or email, if the patient prefers) for 6 months. Contacts are planned to be at weekly or two-weekly intervals, although the frequency will be reviewed in relation to the patient's needs and actual intervals will be recorded. During the follow-up, the participant's PCP will be reviewed with particular emphasis on mutually prioritised problems and new goals will be set in collaboration with the participant as appropriate; each telephone follow-up session is planned to last between 10 and 30 min, but actual durations will be recorded.

Comparator
==========

Participants randomised to the control group will receive treatment as usual by their GP and any other relevant professionals including the full range of physical and mental healthcare services that may be available in their locality.

Measures
========

Participants will be followed up at 1-, 6- and 12-months post randomisation.

The primary outcome measure is depression status and severity identified by the depression subscale items of the Hospital Anxiety and Depression Scale (HADS) \[[@B24]\]. This rating scale is comprised of seven items and has been widely used to examine depression in community populations and particularly among people with co-existing medical conditions.

Additionally a number of secondary outcome measures will be used to examine the efficacy of this intervention and the appropriateness and acceptability of measurement instruments (Table [1](#T1){ref-type="table"}). These will include measures of CHD symptoms, well-being and quality of life, and use of health services. These variables will all be measured at baseline, and the three follow-up time-points.

###### 

Measures used at each time point in the UPBEAT-UK randomised controlled trial

  **Outcome Parameter**              **Instruments**
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  **Primary Outcome**                 
  Depression                         HADS-depression subscale \[[@B24]\]
  **Secondary Outcomes**              
  Depression                         PHQ-9 \[[@B29]\]
  Coronary Heart Disease             Modified Rose Angina Questionnaire \[[@B26]\], Specific Activity Schedule \[[@B30]\], Guy's Hospital Chest Pain Questionnaire \[[@B31]\]
  Quality of Life                    Euroqol 5day \[[@B32]\], Medical Outcomes Survey Short Form-12 (SF-12) \[[@B33]\]
  Adherence to medication            Adapted version of Morisky adherence questionnaire \[[@B34]\]
  Life events                        List of Threatening Events Questionnaire \[[@B35]\]
  Social problems                    Social Problems Questionnaire \[[@B36]\]
  Health Service Utilisation         Client Service Receipt Inventory (CSRI) \[[@B37]\]
  Illness Perceptions                Brief Illness Perceptions Questionnaire \[[@B38]\]
  Participants' problem priorities   Psychlops \[[@B39]\]
  Wellbeing                          Warwick-Edinburgh Mental Well-being Scale \[[@B40]\]

Blinding
========

In a randomised comparison of this type, patient blinding is clearly impossible. The researchers will however be blind to randomisation status, and will be asked to give their opinion on randomisation status to determine whether blinding is adequate. If researcher unblinding occurs, a pair of patients (including the patient whose allocation status may have been identified) will be switched to another researcher within the team.

Statistical analysis
====================

Descriptive analyses will be used to provide summary estimates of outcome measures, focussing on the dropout rate at each time point. A linear mixed effect model for longitudinal data will be used to estimate (using maximum likelihood) between treatment arms the difference in HADS-D scores at 1, 6 and 12 months overall (taking account of any time trends). Intention to treat analysis will be used. While the sample size will not be sufficient to test clustering effects formally, sources of clustering (such as the patient's GP practice) and approximate size of inter-cluster correlation coefficient will be identified so that they can be taken into account in any future definitive trial.

Results of recruitment
======================

Recruitment ceased in May 2011. The recruitment target was achieved, with 81 eligible patients from 15 practices consenting to participation. Figure [2](#F2){ref-type="fig"} details recruitment at each stage, reasons for exclusion and numbers randomised.

![Consort diagram: recruitment and treatment group allocation.](1471-244X-12-58-2){#F2}
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Discussion
==========

This pilot RCT recruited 81 participants within the South London area over an 8-month period. The recruitment method using structured searches of general practice QOF databases for potential participants who were then approached by means of a letter sent by the practice resulted in the planned number of patients being recruited. This method of recruitment therefore appears to be feasible and effective. The ease of recruitment of both practices and patients suggests that the intervention is perceived as acceptable and potentially useful by both clinicians and depressed people with CHD (Fig. [2](#F2){ref-type="fig"}).

The intervention has been designed on the basis of a qualitative examination of patient and provider views and reviews of approaches to managing depression and long-term conditions in primary care. It aims to address health and social care needs in a practical, achievable and patient-focused way. The numbers recruited should allow us to examine the feasibility and acceptability of this approach to care, to ascertain the size of effects associated with this intervention and to determine the optimum design of a definitive trial. Direct contact with patients not opting in may have improved recruitment even further as it is possible that depressed patients may have not replied even if they had been potentially interested in the intervention.
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